Trial Profile
Phase 1 Trial of ADI-PEG 20 plus Cisplatin in Patients with Metastatic Melanoma or other Advanced Solid Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Mar 2021
Price :
$35
*
At a glance
- Drugs Pegargiminase (Primary) ; Cisplatin
- Indications Biliary cancer; Carcinoma; Endometrial cancer; Liver cancer; Malignant melanoma; Ovarian cancer; Solid tumours; Uveal melanoma
- Focus Adverse reactions
- Sponsors Polaris Pharmaceuticals
- 05 Mar 2021 Results published in the British Journal of Cancer
- 24 Feb 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 01 Oct 2015 Planned End Date changed from 1 Jun 2016 to 1 Feb 2017, as reported by ClinicalTrials.gov.